For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.

Among over 125,000 patients, 53.6% discontinued their GLP-1 receptor agonist by 1 year, and these rates were significantly ...

GLP-1 medications have become popular for weight loss, and for good reason—they can help regulate appetite and support weight ...

Amycretin, a novel once-weekly subcutaneous GLP-1 and amylin receptor agonist, was safe compared with other incretin-based ...

"The body of evidence for the GLP-1 drug class shows that up to 40% of total weight loss in GLP-1 patients is lean body mass including skeletal muscle mass, 1" said Mitchell Glass, M.D., President ...

GLP-1 receptor agonists (like Wegovy and Mounjaro) have gained global attention for their ability to help people shed significant weight. These weight loss medications, administered via injections ...

This year, even more Americans are resolving to achieve a healthy weight, and the use of weight loss medications has become more prevalent. Hy-Vee Dietitian Hannah Anderson reviews GLP-1 receptor ...